​​​​​​​Biogen soars as Alzheimer’s approval cheers investors | Curio
News and insights read out for you.
10,000+ audio articles. 50+ world-leading publications.

All in 1 subscription.

Bloomberg logo

​​​​​​​Biogen soars as Alzheimer’s approval cheers investors

11 mins | Jun 11, 2021
story image

Could this be the start of a cure for dementia? Biogen shares have rocketed after its Alzheimer’s antibody therapy was approved by U.S. regulators. Here, Robert Langreth explores the uncertainties surrounding the treatment that could dramatically change treatment for the debilitating brain condition.

For more articles like this please visit us at www.bloomberg.com

Get unlimited access free for 7 days, then $6.67/month (billed annually)
Get started